| Deborah Marie Sarratori, NP | |
|
835 Hopkins Rd, Williamsville, NY 14221-2322 | |
| (716) 688-0500 | |
| Not Available |
| Full Name | Deborah Marie Sarratori |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 835 Hopkins Rd, Williamsville, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043267388 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | F420437-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Deborah Marie Sarratori, NP 835 Hopkins Rd, Williamsville, NY 14221-2322 Ph: (716) 688-0500 | Deborah Marie Sarratori, NP 835 Hopkins Rd, Williamsville, NY 14221-2322 Ph: (716) 688-0500 |
News Archive
Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However, results from the SENIOR trial found that compared with BMS, shorter DAPT combined with the Synergy bioabsorbable polymer DES leads to less adverse events without increasing bleeding risk.
A draft agreement that would ensure countries would share virus samples in exchange for access to affordable vaccines derived from such samples in the event of a pandemic is nearly complete, senior diplomats told Reuters on Thursday.
Stevens Institute of Technology has signed an exclusive licensing agreement with Bonbouton, giving the cutting-edge health and technology company the right to use and further develop a graphene sensing system that detects early signs of foot ulcers before they form so people living with diabetes can access preventative healthcare and confidently manage their health.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 6 days ago
Sally Kammerer, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2250 Wehrle Dr, Suite 1, Williamsville, NY 14221 Phone: 716-276-2123 Fax: 716-276-2129 | |
Stephanie Springborn, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2250 Wehrle Dr, Siute 1, Williamsville, NY 14221 Phone: 716-276-2123 Fax: 716-276-2129 | |
Judith Domanski, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2250 Wehrle Dr Ste 1, Williamsville, NY 14221 Phone: 716-276-2123 | |
Ariel Tatar, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2250 Wehrle Dr, Williamsville, NY 14221 Phone: 716-276-2123 | |
Mrs. Amy M Wynne, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 56 Columbia Dr, Williamsville, NY 14221 Phone: 716-839-0399 | |
Sandra M Leinweber, N.P. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 5820 Main St, Suite 204, Williamsville, NY 14221 Phone: 716-616-0069 | |
Guinivere Flis, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2250 Wehrle Dr Ste 1, Williamsville, NY 14221 Phone: 716-276-2123 |